Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
9.94
+0.03 (0.30%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Zenas BioPharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Zenas BioPharma stock have an average target of 32.29, with a low estimate of 19 and a high estimate of 45. The average target predicts an increase of 224.85% from the current stock price of 9.94.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 20, 2025.
Analyst Ratings
The average analyst rating for Zenas BioPharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Initiates $35 | Buy | Initiates | $35 | +252.11% | Mar 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +352.72% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +201.81% | Mar 12, 2025 |
| Wolfe Research | Wolfe Research | Buy Initiates $19 | Buy | Initiates | $19 | +91.15% | Feb 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +201.81% | Dec 16, 2024 |
Financial Forecast
Revenue This Year
n/a
from 5.00M
Revenue Next Year
7.29M
EPS This Year
-4.59
from -11.89
EPS Next Year
-4.48
from -4.59
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | 18.0M | 147.3M |
| Avg | n/a | 7.3M | 75.4M |
| Low | n/a | n/a | 34.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 1,921.1% |
| Avg | - | - | 933.9% |
| Low | - | - | 374.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -4.27 | -3.81 | -3.72 |
| Avg | -4.59 | -4.48 | -4.06 |
| Low | -5.30 | -5.09 | -4.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.